Skip to Content

Community

Fostering impactful
connections

I’ve learned over the years—a lot of what I do to manage my health works. There’s no way I’m going to stop the progression, but I’ve proven to myself that I can mitigate some of the symptoms through diet, exercise, and attitude.

Leslie, California
DM1 support group and podcast host, living with DM1 quotes
patient-Leslie

We have therapy together every week. We call it ‘couples’ therapy. We are basically a package deal. We live very well together. ~ CHAD

He needs me. ~ MICHAEL

Chad & Michael, Utah
Brothers living with DM1 quotes
patient-Chad & Michael

The worst part of this whole thing is how it passes down to the next generation.

Jubal, North Carolina
Retired University Writing and Literature professor, advocate, and father living with DM1 quotes
patient-Jubal

PepGen and the
Neuromuscular
Disorder Community

The patient advocacy team at PepGen ensures PepGen employees understand the goals, preferences, and unmet needs of the neuromuscular disorder communities we serve. We partner with the community to gain insights that help inform our clinical trial designs; the preferred methods, styles, and frequency of communications; and how our clinical development plans meet the needs of the community.

Community advisory boards, participating with advocacy groups in conferences and awareness activities, and taking part in advocacy-led consortia and working groups enable us to engage and learn from the community.

Contact the PepGen Patient
Advocacy Team

  • Jane Larkindale
    Jane Larkindale, VP, Clinical Science
  • Alayna Tress
    Alayna Tress, Director, Patient Advocacy

We are continually looking to build new relationships with advocacy groups and members of the neuromuscular disorder community. If you’d like to partner with us or have any questions, contact community@pepgen.com.

Community Partners

Community
Community
Community
Community
Community
Community
Community

To learn about partnering with PepGen’s community team, please email us at community@pepgen.com.

Myotonic Dystrophy Type 1 (DM1)

PepGen is committed to transforming the treatment for people living with myotonic dystrophy type 1 (DM1) with our Enhanced Delivery Oligonucleotides (EDOs). 

Oligonucleotides are genetic medicines that have the potential to modify the root cause of numerous neuromuscular disorders. They have been studied for multiple decades, however, by themselves, they do not enter into muscles easily and effectively.

PepGen has developed peptides that can be conjugated (connected) to oligonucleotides, to enhance and improve the delivery and activity of the oligonucleotides.

Preclinical and preliminary clinical data support further clinical development of PGN-EDODM1 in people living with DM1.

Learn more here

See our FAQ for additional resources and information.

DM1 Community FAQs

Professor PepGen

PepGen’s educational series on all things clinical trials. Watch here:

The 5 W's of Clinical Trials

Professor PepGen Lesson 1

The Phases of Rare Disease Clinical Trials

Professor PepGen Lesson 2

Clinical Trial Dictionary

Professor PepGen Lesson 3

The 10 Meter Walk/Run Test

Professor PepGen Lesson 5

What Groups Are Involved in Running a Clinical Trial?

Professor PepGen Lesson 6